Tango Therapeutics, Inc. SEC filings TNGX

Tango Therapeutics, Inc. has 424 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Tango Therapeutics, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 17, 2026 Dec 31, 2025
10-K Annual report Mar 5, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 22, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 29, 2024 Dec 31, 2023
10-K Annual report Mar 18, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 24, 2023 Dec 31, 2022
10-K Annual report Mar 27, 2023 Dec 31, 2022
10-K Annual report Mar 28, 2022 Dec 31, 2021
10-K Annual report Mar 31, 2021 Dec 31, 2020

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TNGX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1819133
Former names
BCTG Acquisition Corp. (until Aug 9, 2021)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.